Gautschi, Oliver

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 33.

Journal Article

Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus; Gautschi, Oliver (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland. PharmacoEconomics, 41(12), pp. 1641-1655. Springer 10.1007/s40273-023-01305-3

Allmann, Valentina; Dyntar, Daniela; Lehnick, Dirk; Dressler, Marco; Zeidler, Kristin; Niederberger, Philipp; Godau, Jeanne; Diebold, Joachim; Gautschi, Oliver (2023). Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. Swiss medical weekly, 153(40039), p. 40039. EMH Schweizerischer Ärzteverlag 10.57187/smw.2023.40039

Mushtaq, Rao; Cortot, Alexis B; Gautschi, Oliver; Mazieres, Julien; Camidge, D Ross (2022). PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series. Translational lung cancer research, 11(12), pp. 2412-2417. AME Publishing 10.21037/tlcr-22-329

Froesch, Patrizia; Mark, Michael; Rothschild, Sacha I; Li, Qiyu; Godar, Gilles; Rusterholz, Corinne; Oppliger Leibundgut, Elisabeth; Schmid, Sabine; Colombo, Ilaria; Metaxas, Yannis; König, David; Sessa, Cristiana; Gautschi, Oliver; Früh, Martin (2021). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung cancer, 156, pp. 91-99. Elsevier 10.1016/j.lungcan.2021.04.002

Peters, Solange; Danson, Sarah; Hasan, Baktiar; Dafni, Urania; Reinmuth, Niels; Majem, Margarita; Tournoy, Kurt G; Mark, Michael T; Pless, Miklos; Cobo, Manuel; Rodriguez-Abreu, Delvys; Falchero, Lionel; Moran, Teresa; Ortega Granados, Ana Laura; Monnet, Isabelle; Mohorcic, Katja; Sureda, Bartomeu Massutí; Betticher, Daniel; Demedts, Ingel; Macias, Jose Antionio; ... (2020). A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. Journal of thoracic oncology, 15(10), pp. 1647-1656. Elsevier 10.1016/j.jtho.2020.06.011

von Garnier, Christophe; Gasche-Soccal, Paola; Beigelmann-Aubry, Catherine; Frauenfelder, Thomas; Gautschi, Oliver; Opitz, Isabelle; Tomonaga, Yuki; Neuner-Jehle, Stefan; Senn, Oliver; Turk, Alexander; Puhan, Milo (2019). Lungenkarzinom-Screening: Heute, morgen oder nie? Info@Onkologie, 2019(4), pp. 44-46. Aerzteverlag medinfo AG

Früh, Martin; Betticher, Daniel C; Stupp, Roger; Xyrafas, Alexandros; Peters, Solange; Ris, Hans Beat; Mirimanoff, Rene Olivier; Ochsenbein, Adrian F.; Schmid, Ralph; Matzinger, Oscar; Stahel, Rolf A; Weder, Walter; Guckenberger, Matthias; Rothschild, Sacha I; Lardinois, Didier; Mach, Nicholas; Mark, Michael; Gautschi, Oliver; Thierstein, Sandra; Biaggi Rudolf, Christine; ... (2019). Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). Journal of thoracic oncology, 14(1), pp. 115-123. Elsevier 10.1016/j.jtho.2018.09.011

Panje, Cedric M; Dedes, Konstantin J; Matter-Walstra, Klazien; Schwenkglenks, Matthias; Gautschi, Oliver; Siano, Marco; Aebersold, Daniel; Plasswilm, Ludwig; Lupatsch, Judith E (2018). A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiotherapy and oncology, 129(2), pp. 257-263. Elsevier 10.1016/j.radonc.2018.07.017

Delaunay, Myriam; Cadranel, Jacques; Lusque, Amélie; Meyer, Nicolas; Gounant, Valérie; Moro-Sibilot, Denis; Michot, Jean-Marie; Raimbourg, Judith; Girard, Nicolas; Guisier, Florian; Planchard, David; Metivier, Anne-Cécile; Tomasini, Pascale; Dansin, Eric; Pérol, Maurice; Campana, Marion; Gautschi, Oliver; Früh, Martin; Fumet, Jean-David; Audigier-Valette, Clarisse; ... (2017). Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European respiratory journal, 50(2) European Respiratory Society 10.1183/13993003.00050-2017

Gautschi, Oliver; Rothschild, Sacha I; Li, Qiyu; Matter-Walstra, Klazien; Zippelius, Alfred; Betticher, Daniel C; Früh, Martin; Stahel, Rolf A; Cathomas, Richard; Rauch, Daniel; Pless, Miklos; Peters, Solange; Froesch, Patrizia; Zander, Thilo; Schneider, Martina; Biaggi, Christine; Mach, Nicolas; Ochsenbein, Adrian (2017). Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clinical lung cancer, 18(3), pp. 303-309. Elsevier 10.1016/j.cllc.2016.11.007

Rothschild, Sacha; Gautschi, Oliver; Batliner, Jasmin; Gugger, Mathias; Fey, Martin; Tschan, Mario (2017). MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors. Lung cancer, 107, pp. 73-83. Elsevier 10.1016/j.lungcan.2016.06.004

Peters, Solange; Stahel, Rolf A; Dafni, Urania; Aix, Santiago Ponce; Massutí, Bartomeu; Gautschi, Oliver; Coate, Linda; López Martín, Ana; van Heemst, Robbert; Berghmans, Thierry; Meldgaard, Peter; Cobo Dols, Manuel; Noguera, Javier Garde; Curioni-Fontecedro, Alessandra; Rauch, Daniel; Mark, Michael T; Cuffe, Sinead; Biesma, Bonne; van Henten, Arjen Mj; Vidal, Óscar Juan; ... (2017). Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung trial. Journal of thoracic oncology, 12(4), pp. 752-762. Elsevier 10.1016/j.jtho.2016.12.017

Stahel, Rolf A; Riesterer, Oliver; Xyrafas, Alexandros; Opitz, Isabelle; Beyeler, Michael; Ochsenbein, Adrian; Früh, Martin; Cathomas, Richard; Nackaerts, Kristiaan; Peters, Solange; Mamot, Christoph; Zippelius, Alfred; Mordasini, Carlo; Caspar, Clemens B; Eckhardt, Katrin; Schmid, Ralph; Aebersold, Daniel; Gautschi, Oliver; Nagel, Wolfgang; Töpfer, Michael; ... (2015). Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. The lancet oncology, 16(16), pp. 1651-1658. Elsevier 10.1016/S1470-2045(15)00208-9

Pless, Miklos; Stupp, Roger; Ris, Hans-Beat; Stahel, Rolf A; Weder, Walter; Thierstein, Sandra; Gerard, Marie-Aline; Xyrafas, Alexandros; Früh, Martin; Cathomas, Richard; Zippelius, Alfred; Roth, Arnaud; Bijelovic, Milorad; Ochsenbein, Adrian; Meier, Urs R; Mamot, Christoph; Rauch, Daniel; Gautschi, Oliver; Betticher, Daniel C; Mirimanoff, René-Olivier; ... (2015). Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet, 386(9998), pp. 1049-1056. Elsevier 10.1016/S0140-6736(15)60294-X

Stutz, Emanuel; Gautschi, Oliver; Fey, Martin F.; Gugger, Mathias; Tschan, Mario; Rothschild, Sacha I. (2014). Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology. Future oncology, 10(2), pp. 211-217. Future Medicine Ltd. 10.2217/fon.13.179

Frauenfelder, T; Puhan, M A; Lazor, R; Von Garnier, Christophe; Bremerich, J; Niemann, T; Christe, Andreas; Montet, X; Gautschi, Oliver; Weder, Bruno J.; Kohler, Martin (2014). Early detection of lung cancer: a statement from an expert panel of the Swiss university hospitals on lung cancer screening. Respiration, 87(3), pp. 254-264. Karger 10.1159/000357049

Baty, Florent; Rothschild, Sacha; Früh, Martin; Betticher, Daniel; Dröge, Cornelia; Cathomas, Richard; Rauch, Daniel; Gautschi, Oliver; Bubendorf, Lukas; Crowe, Susanne; Zappa, Francesco; Pless, Miklos; Brutsche, Martin; Swiss Group for Clinical Cancer Research, on behalf of the (2013). EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer. PLoS ONE, 8(9), e72966. Public Library of Science 10.1371/journal.pone.0072966

Rothschild, Sacha I; Tschan, Mario P; Jaggi, Rolf; Fey, Martin F; Gugger, Mathias; Gautschi, Oliver (2012). MicroRNA-381 Represses ID1 and is Deregulated in Lung Adenocarcinoma. Journal of thoracic oncology, 7(7), pp. 1069-77. Hagerstown, Md.: Wolters Kluwer Health/Lippincott Williams & Wilkins 10.1097/JTO.0b013e31824fe976

Zappa, Francesco; Droege, Cornelia; Betticher, Daniel; von Moos, Roger; Bubendorf, Lukas; Ochsenbein, Adrian; Gautschi, Oliver; Oppliger Leibundgut, Elisabeth; Froesch, Patrizia; Stahel, Rolf; Hess, Thomas; Rauch, Daniel; Schmid, Petra; Mayer, Michael; Crowe, Susanne; Brauchli, Peter; Ribi, Karin; Pless, Miklos; on behalf of the Swiss Group for Clinical Cancer Research (SAKK), (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung cancer, 78(3), pp. 239-44. Amsterdam: Elsevier 10.1016/S1359-6349(09)71860-9

Rothschild, Sacha I; Kappeler, Andreas; Ratschiller, Daniel; Betticher, Daniel C; Tschan, Mario P; Gugger, Mathias; Gautschi, Oliver (2011). The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer. Lung cancer, 71(3), pp. 306-11. Amsterdam: Elsevier 10.1016/j.lungcan.2010.06.018

Ghadjar, Pirus; Burkhard, Fiona C; Gautschi, Oliver; Thalmann, George N; Studer, Urs E (2011). Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU international, 107(6), pp. 894-7. Oxford: Blackwell Science 10.1111/j.1464-410X.2010.09574.x

Ruhstaller, Thomas; Pless, Miklos; Dietrich, Daniel; Kranzbuehler, Helmut; von Moos, Roger; Moosmann, Peter; Montemurro, Michael; Schneider, Paul M; Rauch, Daniel; Gautschi, Oliver; Mingrone, Walter; Widmer, Lucas; Inauen, Roman; Brauchli, Peter; Hess, Viviane (2011). Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). Journal of clinical oncology, 29(6), pp. 626-31. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.31.9715

Rothschild, Sacha I; Gautschi, Oliver; Haura, Eric B; Johnson, Faye M (2010). Src inhibitors in lung cancer: current status and future directions. Clinical lung cancer, 11(4), pp. 238-42. New York, N.Y.: Elsevier 10.3816/CLC.2010.n.030

Gautschi, Oliver (2010). The polyamine metabolism: renaissance of an old pathway in oncology. Clinical lung cancer, 11(2), pp. 80-1. New York, N.Y.: Elsevier 10.3816/CLC.2010.n.010

Purnell, Phillip R; Mack, Philip C; Tepper, Clifford G; Evans, Christopher P; Green, Tim P; Gumerlock, Paul H; Lara, Primo N; Gandara, David R; Kung, Hsing-Jien; Gautschi, Oliver (2009). The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. Journal of thoracic oncology, 4(4), pp. 448-54. Hagerstown, Md.: Wolters Kluwer Health/Lippincott Williams & Wilkins 10.1097/JTO.0b013e31819c78fb

Ho, Cheryl; Ochsenbein, Adrian F; Gautschi, Oliver; Davies, Angela M (2008). Early clinical trial experience with vaccine therapies in non-small-cell lung cancer. Clinical lung cancer, 9 Suppl 1, S20-S27. New York, N.Y.: Elsevier 10.3816/CLC.2008.s.004

Gautschi, Oliver; Heighway, Jim; Mack, Philip C; Purnell, Phillip R; Lara, Primo N; Gandara, David R (2008). Aurora kinases as anticancer drug targets. Clinical cancer research, 14(6), pp. 1639-48. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-07-2179

Gautschi, Oliver; Tepper, Clifford G; Purnell, Phillip R; Izumiya, Yoshihiro; Evans, Christopher P; Green, Tim P; Desprez, Pierre Y; Lara, Primo N; Gandara, David R; Mack, Philip C; Kung, Hsing-Jien (2008). Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer research, 68(7), pp. 2250-8. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-07-6403

Gautschi, Oliver; Ratschiller, Daniel; Gugger, Mathias; Betticher, Daniel C; Heighway, Jim (2007). Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung cancer, 55(1), pp. 1-14. Amsterdam: Elsevier 10.1016/j.lungcan.2006.09.024

Ziegler, Annemarie; Seemayer, Christian A; Hinterberger, Marc; Vogt, Peter; Bigosch, Colette; Gautschi, Oliver; Tornillo, Luigi; Betticher, Daniel C; Moch, Holger; Stahel, Rolf A (2007). Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results. Lung cancer, 57(3), pp. 282-91. Amsterdam: Elsevier 10.1016/j.lungcan.2007.03.025

Gandara, David R; Davies, Angela M; Gautschi, Oliver; Mack, Philip C; Lau, Derick H; Lara, Primo N; Hirsch, Fred R (2007). Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clinical lung cancer, 8 Suppl 2, S61-S67. New York, N.Y.: Elsevier 10.3816/CLC.2007.s.003

Gautschi, Oliver; Hugli, Barbara; Ziegler, Annemarie; Bigosch, Colette; Bowers, Naomi L; Ratschiller, Daniel; Jermann, Monika; Stahel, Rolf A; Heighway, Jim; Betticher, Daniel C (2006). Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung cancer, 51(3), pp. 303-11. Amsterdam: Elsevier 10.1016/j.lungcan.2005.10.025

Gautschi, Oliver; Zangemeister-Wittke, U.; Stahel, R. A. (2003). Comment on “A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer”, by C. M. Rudin et al. (Ann Oncol 2002; 13: 539–545). Annals of oncology, 14(1), p. 170. Oxford University Press 10.1093/annonc/mdg001

This list was generated on Thu Mar 28 09:58:47 2024 CET.
Provide Feedback